Your browser doesn't support javascript.
loading
Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial.
Tameris, Michele; Mearns, Helen; Penn-Nicholson, Adam; Gregg, Yolande; Bilek, Nicole; Mabwe, Simbarashe; Geldenhuys, Hennie; Shenje, Justin; Luabeya, Angelique Kany Kany; Murillo, Ingrid; Doce, Juana; Aguilo, Nacho; Marinova, Dessislava; Puentes, Eugenia; Rodríguez, Esteban; Gonzalo-Asensio, Jesús; Fritzell, Bernard; Thole, Jelle; Martin, Carlos; Scriba, Thomas J; Hatherill, Mark.
Afiliación
  • Tameris M; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Mearns H; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Penn-Nicholson A; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Gregg Y; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Bilek N; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Mabwe S; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Geldenhuys H; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Shenje J; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Luabeya AKK; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Murillo I; Biofabri, Pontevedra, Spain.
  • Doce J; Biofabri, Pontevedra, Spain.
  • Aguilo N; Department of Microbiology, Faculty of Medicine, University of Zaragoza, Zaragoza, Spain; CIBERES and Research Network on Respiratory Diseases, Spanish Ministry of Health and Instituto de Salud Carlos III, Madrid, Spain.
  • Marinova D; Department of Microbiology, Faculty of Medicine, University of Zaragoza, Zaragoza, Spain; CIBERES and Research Network on Respiratory Diseases, Spanish Ministry of Health and Instituto de Salud Carlos III, Madrid, Spain.
  • Puentes E; Biofabri, Pontevedra, Spain.
  • Rodríguez E; Biofabri, Pontevedra, Spain.
  • Gonzalo-Asensio J; Department of Microbiology, Faculty of Medicine, University of Zaragoza, Zaragoza, Spain; CIBERES and Research Network on Respiratory Diseases, Spanish Ministry of Health and Instituto de Salud Carlos III, Madrid, Spain.
  • Fritzell B; Tuberculosis Vaccine Initiative, Lelystad, Netherlands.
  • Thole J; Tuberculosis Vaccine Initiative, Lelystad, Netherlands.
  • Martin C; Department of Microbiology, Faculty of Medicine, University of Zaragoza, Zaragoza, Spain; CIBERES and Research Network on Respiratory Diseases, Spanish Ministry of Health and Instituto de Salud Carlos III, Madrid, Spain; Servicio de Microbiología, Hospital Miguel Servet, ISS Aragon, Zaragoza, Spain.
  • Scriba TJ; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Hatherill M; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa. Electronic address: mark.hatherill@uct.ac.za.
Lancet Respir Med ; 7(9): 757-770, 2019 09.
Article en En | MEDLINE | ID: mdl-31416768
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Tuberculosis / Vacuna BCG / Vacunas contra la Tuberculosis Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Female / Humans / Male / Middle aged País/Región como asunto: Africa Idioma: En Revista: Lancet Respir Med Año: 2019 Tipo del documento: Article País de afiliación: Sudáfrica
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Tuberculosis / Vacuna BCG / Vacunas contra la Tuberculosis Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Female / Humans / Male / Middle aged País/Región como asunto: Africa Idioma: En Revista: Lancet Respir Med Año: 2019 Tipo del documento: Article País de afiliación: Sudáfrica